Latest From Michael McCaughan
Biopharma industry is making some modest headway in quest to change the new US Medicare drug price process to treat drugs and biologics on equal footing. But eliminating the so-called ‘pill penalty’ would not on its own equalize the incentives for small molecule and large molecule R&D.
New drug pricing program under the Inflation Reduction Act could reduce the value of the 340B drug discount for safety net providers by as much as $1 billion in the first year, an analysis by the 340B Health association suggests.
The head of the federal agency overseeing the 340B drug discount program offers unusually direct calls for legislative action during the safety net provider association winter conference. But is action likely in Congress any time soon?
Biogen’s decision to discontinue is Alzheimer’s treatment Aduhelm cements its status as one of the most spectacular commercial failures in biopharma history. But its impact on biopharma policy is still extraordinary.
US Medicare Payment Advisory Commission still sees promise in ‘Medication Therapy Management’ programs. But why is the value of enhanced pharmacy support for patients on complex prescription regimens so hard to prove in actual practice?
US Medicare Payment Advisory Commission will be tracking adoption of Humira biosimilars – both because of the direct impact on costs in the Part D program, but also to test whether changes to the benefit design will work to encourage price competition.